A federal review board voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was slim. It is not final. The FDA has given no clear statement on whether it will take up the recommendation. The move came after weeks of public comment sessions. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have little hard evidence of safety or help for most uses. The call could redefine how the agency handles a part of the wellness market that is scaling quickly. Patient groups are waiting to see if the regulator moves in step. A spokesperson offered no fixed date for a reaction. Industry voices argue the change would expand access to substances users swear by. Safety voices warn that looser rules could invite misuse across a fast-scaling market. The advisory vote only plants the seed for a shift, and the final call rests with the federal regulator.